Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

---

**A**

<table>
<thead>
<tr>
<th>Condition</th>
<th>SIRPα</th>
<th>CD47</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Transition</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Low grade dyspl.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>High grade dyspl.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Carcinoma</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Immunodetection**

- Strong
- Intermediate
- Weak
- Negative

**B**

- **Plasma B cells**
- **B cells**
- **CD8+ T cells**
- **CD4+ T cells**
- **T cells undefined**
- **ILCs**
- **Macrophages**
- **Dendritic cells**
- **Monocytes**
- **Granulocytes**
- **Fibroblasts**
- **Vessels**

**Region**

- Normal
- Transition
- Low grade dysplasia
- High grade dysplasia
- Carcinoma

---